evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,771 questions · 10,185 findings · 893 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,109 · 20.7%GRADE not reported 1,125 · 11%Very low 2,279 · 22.4%Low 2,514 · 24.7%Moderate 1,709 · 16.8%High 449 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Overall survival (at 36 months) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower overall survival (at 36 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Progression‐free survival (PSF) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower progression‐free survival (at 24 months) compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Health‐related quality of life European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ‐C30). Scale from: 0 to 100 (a higher score means a better outcome) · people with newly diagnosed multiple myeloma ineligible for transplant
1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Mortality within the longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to lower on‐study mortality (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Serious adverse events at longest · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher serious adverse events (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events (grade ≥ 3) · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy showed no clear difference in adverse events (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Daratumumab plus standard therapy vs usual care

Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant

Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).

1 finding from 1 review

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Death (all causes) · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with neoadjuvant chemotherapy probably leads to lower overall survival Median compared with radiotherapy alone (moderate certainty).

1 finding from 1 review

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Disease or progression‐free survival Median · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in disease‐ or progression‐free survival Median compared with radiotherapy alone (moderate certainty).

1 finding from 1 review

Hysterectomy (simple or radical) with neoadjuvant chemotherapy vs Radiotherapy alone

Severe adverse events and toxicity · women with locally advanced cervical cancer

Hysterectomy (simple or radical) with neoadjuvant chemotherapy showed no clear difference in severe adverse events and toxicity compared with radiotherapy alone (low certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Frequent relapses · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in number with frequent relapses by 12 to 24 months compared with 2 months of therapy (moderate certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Number of children relapsing by 12 to 24 months · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number of children relapsing by 12 to 24 months compared with 2 months of therapy (low certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Number with frequent relapses by 12 to 24 months stratified by risk of selection bias: Low risk of selection bias · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (high certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Number with frequent relapses by 12 to 24 months stratified by risk of bias for allocation concealment: unclear or high risk of bias for allocation bias · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… may leads to lower number with frequent relapses by 12 to 24 months stratified by risk… compared with 2 months of therapy (low certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Adverse events: psychological disorders · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: psychological disorders compared with 2 months of therapy (low certainty).

1 finding from 1 review

Steroid therapy in first episode of nephrotic syndrome: 3 months or more vs 2 months of therapy

Adverse events: hypertension · children with nephrotic syndrome

Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).

1 finding from 1 review